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Ezrin is a scaffolding protein that is involved in oncogenesis by linking cytoskeletal and membrane proteins. Ezrin
interacts with epidermal growth factor receptor (EGFR) in the cell membrane, but little is known about the effects
of this interaction on EGFR signaling pathway. In this study, we established the biological and functional
significance of ezrin-EGFR interaction in non–small cell lung cancer (NSCLC) cells. Endogenous ezrin and EGRF
interaction was confirmed by co-immunoprecipitation and immunofluorescent staining. When expression of ezrin
was inhibited, EGFR activity and phosphorylation levels of downstream signaling pathway proteins ERK and STAT3
were decreased. Cell fractionation experiments revealed that nuclear EGFR was significantly diminished in ezrin-
knockdown cells. Consequently, mRNA levels of EGFR target genes AURKA, COX-2, cyclin D1, and iNOS were
decreased in ezrin-depleted cells. A small molecule inhibitor of ezrin, NSC305787, reduced EGF-induced
phosphorylation of EGFR and downstream target proteins, EGFR nuclear translocation, and mRNA levels of
nuclear EGFR target genes similar to ezrin suppression. NSC305787 showed synergism with erlotinib in wild-type
EGFR-expressing NSCLC cells, whereas no synergy was observed in EGFR-null cells. Phosphorylation of ezrin on
Y146 was found as an enhancer of ezrin-EGFR interaction and required for increased proliferation, colony
formation, and drug resistance to erlotinib. These findings suggest that ezrin-EGFR interaction augments
oncogenic functions of EGFR and that targeting ezrin may provide a potential novel approach to overcome erlotinib
resistance in NSCLC cells.
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Epidermal growth factor receptor (EGFR) activation positively
regulates growth of epithelial cells. The overexpression of EGFR
has been observed in both premalignant and malignant tumors of the
lung and occurs in 40% to 80% of patients with non–small cell lung
cancer (NSCLC) [1,2]. Ligand binding to EGFR results in receptor
dimerization at the plasma membrane leading to activation of the
tyrosine kinase domain and autophosphorylation of the cytoplasmic
tail. Phosphorylation of the cytoplasmic domain of EGFR generates
docking sites for several oncogenic proteins that induce Ras and
PI3K. In addition, Src family tyrosine kinases, phospholipase
C-gamma, protein kinase C, and signal transducers and activators
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EGFR either directly or indirectly [3,4]. Activation of EGFR triggers
receptor internalization and results in degradation or recycling of the
receptor back to the cell surface [5,6].
Nuclear localization of EGFR has been detected in many cancers
including NSCLC cells [7], and research over the last decade
characterized the steps for nuclear EGFR transport. After internal-
ization, full-length EGFR interacts with importin β1 in the early
endosomes via its nuclear localization sequence. This complex then
moves through the Golgi apparatus and endoplasmic reticulum
before it shuttles to the nucleus [8,9].
Nuclear EGFR (nEGFR) interacts with STAT proteins in the
nucleus and acts as a transcriptional coactivator that regulates
expression of several tumor-promoting genes including cyclin D1,
inducible nitric oxide synthase (iNOS), Aurora kinase A (AURKA),
B-Myb, COX-2, c-Myc, breast cancer related protein, and GRP78
[10–12]. nEGFR phosphorylates proliferating cell nuclear antigen to
promote cell proliferation and DNA repair [13]. Interaction of
nEGFR with DNA-dependent protein kinase leads to repair of
radiation-induced double-strand breaks in DNA of bronchial
carcinoma cells [14].
High levels of nEGFR correlate with poor clinical outcome in breast,
ovarian, oropharyngeal, esophageal, gallbladder, and NSCLC patients
[15]. nEGFR is also related to resistance to chemotherapy [7] and
radiotherapy [16]. Therefore, it is important to understand the
mechanisms of nuclear transport of EGFR to target its nuclear functions.
Ezrin is a member of the membrane-cytoskeleton linker
Ezrin-Radixin-Moesin (ERM) family of proteins, which are involved
in the assembly of specialized domains of the membrane. ERM
proteins were originally characterized as structural components of the
cell cortex but were later shown to participate in signaling pathways
[17]. Through their dynamic and reversible interactions with
membrane proteins and actin filaments, ERM proteins coordinate
multiple signal transduction pathways. In particular, ezrin is involved
in trafficking events to and from the plasma membrane and recycling
of transmembrane proteins such as α1-β adrenergic receptor [18],
NHE3 [19], and H-K-ATPase [20]. Ezrin also facilitates nuclear
import of β-dystroglycan [21].
Ezrin overexpression enhances malignant behavior of various
cancer cells. In NSCLC, a high level of ezrin expression is associated
with higher metastatic potential and lower patient survival [22].
Expression levels of ezrin were found to be significantly higher in
primary cancer tissues than matched normal lung tissues [23].
Suppression of ezrin expression in NSCLC cell lines leads to reduced
migration and invasion, anchorage-independent growth ability, and
increased drug sensitivity [24].
Tyrosine phosphorylation of ezrin at Y146 and Y353 after EGF
treatment [25–27], and the interaction between ezrin and EGFR
have been demonstrated previously [28]. Recent findings showed that
C terminal truncated forms of ezrin prohibited EGF-induced
Ras pathway activation [29], and ezrin homolog ERM-1 in Caenor-
habditis elegans regulated EGFR localization and signaling in
vulvar cells [30]. Ezrin is also required for the delivery of EGFR to
the lysosomes [31].
In this study, we show that ezrin enhances signaling and nuclear
transport of EGFR in NSCLC cell lines. We further demonstrate
synergism between a small molecule inhibitor of ezrin, NSC305787,
and an EGFR inhibitor, erlotinib, in these cell lines, which may
influence future therapy directions in NSCLC.Methods
Cell Culture, Oligo Transfection, and Drug Treatment
A549, H292, H520, and H1944 cells were obtained from
Georgetown University Tissue Culture Core Facility, and H2073
cells were kindly provided by Dr. Michael Peyton (UT Southwestern
Medical Center); all cell lines were maintained in RPMI-1640 (Life
Technologies #11875) supplemented with 10% fetal bovine serum
(Sigma-Aldrich, #F2442). Ezrin siRNA (Ambion Life, #s14796) and
ON-TARGETplus nontargeting control siRNA (Dharmacon,
#D001818-02) were transfected using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s protocol. Briefly,
Lipofectamine 2000 and siRNA were diluted in reduced-serum
media, OptiMEM, and incubated for 10 minutes at room
temperature. Diluted siRNA and Lipofectamine 2000 reagent were
then combined in one tube and incubated for another 15 minutes
before being added to the cell plate. For 96-well plate proliferation,
cytotoxicity, and synergy assays, cells were transfected in 10-cm
dishes, split after 48 hours, serum starved, and treated with EGF or
HGF (R&D Systems Inc.) after an additional 24 hours. For the
demonstration of ezrin knockdown via Western blot, cells were lysed
72 hours after transfection.
Erlotinib and etoposide were purchased from Selleckchem, and
NSC305787 was obtained from Developmental Therapeutic Pro-
gram of the National Institutes of Health (Bethesda, MD, USA). For
growth factor–induced experiments, cells were treated with 5 μM
NSC305787 30 minutes before growth factors. For immunoflour-
escence and nuclear fractionation experiments, NSC305787 was
given at 1-μM concentration for 24 hours.
Antibodies
The following antibodies were used for Western blot, immunopre-
cipitation, and immunofluorescence: Ezrin (E8897) from Sigma-
Aldrich; EGFR (#4267), Lamin A/C (#2032), Tubulin (#2144),
phospho-STAT3 (#9131), phospho-ERK (#4370), ERK (#9107),
phospho-EGFR Y1068 (#2236), phospho-EGFR Y845 (#2231),
Myc-tag (#2276), and phospho-ezrin Tyr353 (#3144) from Cell
Signaling; actin (C-11) HRP (sc1615) and mouse IgG (sc2025) from
Santa Cruz Biotechnology; STAT3 (ab50761) and phospho-ezrin
Y146 (ab92507) from Abcam; and Alexa-Fluor mouse (A21235) and
rabbit (A11034) secondary antibodies from Thermo Fisher.
Immunoprecipitation, Cell Fractionation, and Western Blot
Subconfluent cells were lysed with RIPA buffer (50 mM Tris HCl
pH 7.4, 1% Nonidet P-40, 0.5% Na-deoxycholate, 0.1% SDS, 150
mM NaCl, 2 mM EDTA, 50 mM NaF) supplemented with protease
and phosphatase inhibitors and DNase. After protein quantification
using bicinchoninic acid assay, 1 mg of protein was incubated for
2 hours with the indicated antibodies and then for 1 hour at 4°C with
A/G Plus-agarose beads (#sc2001, Santa Cruz Biotechnology). After
each incubation period, samples were washed three times with IP
wash buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40,
0.2 mM sodium vanadate, and 0.2 mM PMSF). To elute the protein
bound to the beads, samples were boiled in SDS-PAGE sample buffer
for 5 minutes. Qproteome Cell Compartment Kit (Qiagen #37502)
was used for cell fractionation according to kit instructions and the
previously described method [32]. Western blot signals were
quantitated by ImageJ64 1.47v software (NIH, USA).
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Coverslips were placed in 12-well plates and precoated with
collagen. Cells were grown on the coverslips, treated if necessary, and
washed twice with 37°C PBS before fixation with 3.7% paraformal-
dehyde in PBS for 15 minutes. The coverslips were then washed with
PBS three times each for 5 minutes, and cells were permeablized and
blocked with 1% BSA, 10% goat serum, and 0.5% Triton X-100 in
PBS for 30 minutes. Next, coverslips were incubated with primary
antibodies diluted in 1% BSA in PBS for 1 hour at room temperature
and washed three times with PBS. Lastly, coverslips were incubated
for 30 minutes in the dark at room temperature with secondary
antibodies and DAPI diluted in PBS. Before mounting with
Flourogel with Tris Buffer (#17985, Electron Microscopy Sciences),
the coverslips were washed three times with PBS and two times with
ddH2O. Images were acquired using a Nikon Eclipse Ti-S
microscope with Nikon Intensilight C-HGFI fiber illuminator
(Nikon Instruments Inc.).
Quantitative Polymerase Chain Reaction (PCR) and Primers
Total RNA was extracted from cell lines using an RNAeasy mini kit
(Qiagen) and reverse transcribed using Transcriptor First Strand cDNA
Synthesis Kit (Roche) according to manufacturer’s protocols. Quanti-
tative PCR was done on an Eppendorf Mastercycler using SYBRGreen
mix (Sigma Aldrich). Reactions were performed in triplicate in a
96-multiwell plate (Eppendorf, #30132700). Gene expressions were
normalized to 18S rRNA, and fold differences were calculated using the
comparative CTmethod: 2−(ΔΔCT), where ΔΔCT refers to (normalized
control sample) − (normalized treated sample). Primer pairs were as
follows—18S rRNA: sense: 5′-cttagagggacaagtggcg-3′, antisense:
5′-acgctgagccagtcagtgta-3′; aurora kinase A: sense: 5′-tctagtcctccttaac
cacttatct-3′, antisense: 5′-gacacatggcctcttctgtatc-3′; COX2: sense:
5′-tgtacccggacaggattcta-3′, antisense: 5′-cccttgaagtgggtaagtatgt-3′;
iNOS: sense: 5′-aaggtctacgttcaagacatcc-3′, antisense: 5′-gcacatcgcca
caaacatag-3′; cyclin D1: sense: 5′-gggttgtgctacagatgatgag-3′, antisense:
5′-agacgcctcctttgtgttaat-3′.
Cell Viability, Proliferation, and Synergy Experiments
NSCLC cells (3.5 × 103 cells/well) were seeded to 96-well plates.
After overnight growth, 0 to 50 mM erlotinib or 0 to 100 μM
NCS305787 (in DMSO) was added; the DMSO level in each sample
was adjusted to 2% for erlotinib and 1% for NSC305787. After 24
hours of incubation, 0.5 mg/ml thiazolyl blue tetrazolium bromide
(MTT; Sigma-Aldrich, #M5655) was added to the media and
incubated for an additional 4 hours. Then, the media was aspirated,
and 100 μl of isopropanol was added to each well. The plates were
shaken before light absorbance was measured at 570 and 650 nm
using a plate reader, and IC50 values were calculated using GraphPad
Prism 6 software (GraphPad Software, Inc.).
For synergy experiments, 50 μM erlotinib, 20 μM NSC305787,
and 40 μM etoposide were used for the maximum concentrations,
and cells were treated with drugs in serial dilutions in seven
concentrations either alone or in combined form. DMSO concen-
trations in synergy plates were adjusted to the highest DMSO
concentration (2.5%) in the plate for each synergy experiment. After
absorbance measurements were taken, affected fractions (Fa) were
calculated separately for each triplicate treatment according to the
Chou-Talalaymethod [33] using the formula 1 − (X - blank)/(DMSO −
blank): X represents the average of each triplicated treatment, and blank
represents the background measurement at 650 nm. CombinationIndex (CI) calculations were made using CompuSyn software
(ComboSign, Inc.).
Plasmid Constructs and Site-Directed Mutagenesis
The pcDNA3.1 plasmids encoding myc- and his-tagged ezrin
Y146E, Y146F, Y353E, and Y353F were created by site-directed
mutagenesis using WT ezrin as a template. The following primers
were designed using the QuikChange Primer Design web tool
(Agilent Technologies): Y146E: sense: 5′-ccgctcagagctgagttcccca
gacttgtgcac-3′, antisense: 5′-gtgcacaagtctggggaactcagctctgagcgg-3′;
Y146F: sense: 5′-ccgctcagagctgagttccccagacttgtgcac-3′, antisense:
5′-gtgcacaagtctggggaactcagctctgagcgg-3′; Y354E: sense: 5′-ttctttgtct
tctcctcttcgtcctgcagccgcagc-3′, antisense: 5′-gctgcggctgcaggacgaagag
gagaagacaaagaa-3′; Y354F: sense: 5′-cttctcctcaaagtcctgcagccgcagca-
3′, antisense: 5′-tgctgcggctgcaggactttgaggagaag-3′. QuikChange II XL
site-directed mutagenesis kit (Agilent Technologies) was used according
to the manufacturers’ instructions. Cells were transfected using
FuGENE 6 transfection reagent (Promega Corporation) and selected
with G418 (Geneticin; Life Technologies) for 7 to 10 days before
splitting for experiments.
Soft Agar Colony Formation Assay
The bottom layer was prepared with 0.6% agar-containing media
in 12 well plates, and 1 × 103 cells were mixed with 0.4%
agar-containing media and added to the plates in the top layer.
Colonies were detected after 3 weeks of incubation at 37°C in a
humidified atmosphere. Pictures of soft agar colonies were analyzed
using ImageJ64 1.47v software (NIH, USA).
Statistical Analysis
Statistical analyses were performed using GraphPad Prisim 6
(GraphPad Software, Inc, CA, USA). Unpaired t test with Welch’s
correction was used for comparison of two different conditions.
Results
Ezrin-EGFR Interaction in NSCLC Cells
We first validated the interaction between endogenous ezrin and
EGFR in two wild-type (wt) EGFR-expressing NSCLC cell lines,
A549 and H292, in the presence and absence of the ligand EGF
(Figure 1A). We were able to detect ezrin and EGFR in the same
protein complex that was immunoprecipitated by an anti-ezrin
antibody (Figure 1A, lane 2 compared with lane 3), and this
interaction was increased in EGF-stimulated cells (Figure 1A, lane 3
compared with lane 9). This enhancement may be due to the increase
in the total level of EGFR in EGF-stimulated cells (Figure 1A, lane 1
compared with lane 7).
Next, we evaluated the effect of NSC305787, a small molecule
inhibitor of ezrin, which functions through preventing specific
protein-protein interactions of ezrin [5,32]. NSC305787 inhibited
EGFR binding to ezrin in both the presence and absence of EGF
(Figure 1A, lane 3 compared with lane 6 and lane 9 compared with
lane 12). To further examine the effect of NSC305787 on the
interaction between ezrin and EGFR, we analyzed localization
patterns of ezrin and EGFR by immunofluorescence staining.
Ezrin-EGFR colocalization was visible on both the plasma membrane
and the perinuclear area, which was inhibited by NSC305787
treatment. We also observed morphological changes in
NSC305787-treated cells, which possibly result from reduced ezrin
levels around the plasma membrane (Figure 1B, lower panel).
Figure 1. Ezrin and EGFR interacts in NSCLC cell lines. (A) H292 cells were serum starved overnight and pretreated with 5 μM ezrin
inhibitor NSC305787 or DMSO for 2 hours followed by 100-ng/ml EGF treatment for 5 minutes. Cell lysates were immunoprecipitated
using an antiezrin antibody or control mouse total IgG. Precipitates were evaluated byWestern blotting using anti-EGFR (upper panel) and
antiezrin (lower panel) antibodies. EGFR interaction with ezrin was enhanced with EGF stimulation, and NSC305787 inhibited this
interaction in both the presence and absence of the ligand. (B) Immunofluorescence staining of EGFR (red), ezrin (green), and DAPI (blue)
in DMSO-treated (upper images) and NSC305787-treated (bottom images) A549 cells was analyzed by fluorescence microscopy. Ezrin
and EGFR colocalization (yellow) in the membrane (arrow) and perinuclear area (arrow head) is indicated. NSC305787 treatment inhibited
the colocalization of ezrin and EGFR.
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To evaluate the effect of ezrin on EGFR phosphorylation, we
silenced ezrin expression in A549 and H292 by small interfering
RNAs. Cells were first serum starved for 24 hours and then treated
with EGF for 5 minutes. Immunoblot analysis revealed that
suppression of ezrin expression resulted in 50% and 40% decrease
in phosphorylation of EGFR (Tyr 1068 and Tyr 845 residues),
respectively (Figure 2A). We also observed an increase in the total
EGFR levels in some of the siEZRIN-treated cells with an average of
40% (±10%). Inhibition of ezrin expression also resulted in reduced
phosphorylation of two EGFR downstream pathway proteins: ERK
and STAT3 (Figure 2B). Reduced levels of phosphorylation of ERK
and STAT3 upon NSC305787 treatment further validated depen-
dency of the EGFR signaling on ezrin. NSC305787 inhibited
EGF-mediated phosphorylation of both STAT3 and ERK in NSCLC
cell lines (Figure 2C) but did not affect ERK phosphorylation levels in
two EGFR-null cell lines (Supplementary Figure S1). NSC305787
also did not affect basal ERK phosphorylation levels in H292 cells
(Supplementary Figure S4).Nuclear EGFR Levels in Ezrin Knockdown Cells
Earlier work suggested that ezrin might regulate endosome
transport and nuclear import of several of its protein binding
partners [21,31]. We hypothesized that ezrin may also have an effect
on the nuclear shuttling of EGFR. To this end, we determined
nEGFR levels in A549 and H292 cells following siRNA-mediated
knockdown of ezrin expression (Figure 3A). Using Image J64
software, we observed 55% and 30% reductions in the pixels of
nEGFR protein levels in response to ezrin siRNA in A549 and H292
cell lines, respectively. We also observed an increase in the
cytoplasmic and total EGFR levels, which might be induced by a
positive feedback mechanism. The decrease in nEGFR levels in
response to ezrin depletion was also validated by immunofluorescence
staining in A549 cells (Figure 3B). Antiezrin compound NSC305787
inhibited the nuclear translocation of EGFR as well (Figure 3C).
Lack of Ezrin Effects nEGFR Target Gene Expression
Because reduced ezrin expression caused a decrease in nEGFR
levels in NSCLC cell lines, we evaluated the mRNA levels of nEGFR
Figure 2. Reduced ezrin expression inhibits EGFR and phosphorylation of downstream target proteins in NSCLC cells. (A) Expression of
ezrin was inhibited using siRNA oligos in A549 and H292 cells. Serum-starved cells were stimulated with 100 ng/ml of EGF for 5 minutes.
EGFR activity was determined by immunoblot using phosphospecific antibodies for Y1068 and Y845. (B) Phosphorylation of EGFR
downstream pathway proteins ERK and STAT3 was determined in cell lysates from panel A. Similar to EGFR, phospho-STAT3 and
phospho-ERK levels were decreased in ezrin-depleted cells. (C) Cells were serum starved for 24 hours and treated with 5 μMNSC305787
or DMSO for 30 minutes before 5 minutes of EGF treatment. Phospho-STAT3 and phospho-ERK protein levels were decreased in
NSC305787-treated cells.
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same cell lines (Figure 4A). RNAi-mediated knockdown of ezrin in
A549 cells decreased AURKA, COX-2, and iNOS expression more
than 50%. A moderate but consistent 20% reduction in CCND1
(cyclin D1) mRNA levels was also observed. Pharmacological
inhibition of ezrin by NSC305787 also decreased AURKA and
COX-2 expression in H292 cells (Figure 4B). There was no significant
decrease in nEGFR target gene expression in NSC305787-treated
H520 cells, which do not express any EGFR, or in H292 cells
without EGF induction (Supplementary Figure S5). Because thosegenes are associated with cell proliferation, we checked the
proliferation of all three NSCCLC cell lines after transfection of
cells with siRNA for ezrin (Figure 4C). Inhibition of ezrin expression
significantly decreased proliferation of wt EGFR-expressing A549 and
H292 cells but had no effect on EGFR-null H520 cells (Figure 4D).
Ezrin and Erlotinib Sensitivity
Erlotinib functions by inhibiting EGFR tyrosine kinase activity in
both EGFR wt and mutant cancer cells. There are several mechanisms
independent of kinase activity that may result in erlotinib resistance in
Figure 3. Inhibition of ezrin expression causes decreased levels of EGFR in nucleus in NSCLC cells. (A) Ezrin expression was inhibited
using siRNA oligos in A549 and H292 cells, and whole cell lysates were subjected to cell fractionation and immunoblotting with antiezrin
and anti-EGFR antibodies. Lamin A/C and tubulin antibodies were used as control for nuclear and non-nuclear fractions, respectively. (B)
Immunofluorescence staining of EGFR, ezrin, and DAPI in control siRNA–treated (left panel) and ezrin siRNA–treated (right panel) A549
cells. Nuclear and perinuclear EGFR localization was decreased in ezrin-depleted cells. (C) Cells were serum starved for 24 hours and
treated with 5 μMNSC305787 or DMSO for 2 hours before EGF stimulation for 30 minutes. NSC305787 decreased EGF-induced nuclear
translocation of EGFR in H292 cells.
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hypothesized that suppression of ezrin expression might sensitize cells
to erlotinib treatment. To test this hypothesis, two NSCLC cells were
transfected with siRNA oligos targeting ezrin and incubated with
increasing concentrations of erlotinib for 24 hours. Ezrin knockdown
significantly decreased the viability of cells and caused a reduction in
IC50 values for erlotinib in both EGFR-expressing cell lines but not
the EGFR-null cell line (Figure 5, A and B). Having demonstrated
that silencing of ezrin expression sensitizes cells to erlotinib treatment,
we then tested the potential synergy between NSC305787 and
erlotinib. We treated the cells with erlotinib alone and in
combination with NSC305787 and determined the cell viability.
Calculation of CIs was performed using Compu-Syn software based
on the Chou-Talalay method [33], where CI b1 indicates synergy.
We observed synergy between NSC305787 and erlotinib in A549(Figure 5C) but not in H520 cell line (Figure 5D). Etoposide was
used as a non-Tyrosine kinase inhibitor control drug, and it did not
show any synergy with NSC305787 (Figure 5E).
Ezrin Y146 Phosphorylation and EGFR Binding
Previous data and our findings in this study show that EGF
treatment might increase the interaction between ezrin and EGFR. It
has been demonstrated that EGF induces tyrosine phosphorylation of
ezrin at Y146 and Y353. We validated increased ezrin phosphory-
lation on Y146 and Y353 residues in A549 cells following EGF
treatment (Figure 6A). We then investigated whether these
phosphorylation events can affect ezrin-EGFR interaction. We
transfected erlotinib-sensitive H2073 cells with mammalian expres-
sion vectors containing cDNA for wt ezrin (Ezrinwt) and mutant
forms of ezrin (Y146E, Y146F, Y353E, and Y353F) with a myc-tag
Figure 4. Suppression of ezrin expression and its pharmacological inhibition by NSC305787 causes decreased mRNA levels of nEGFR
target genes in EGFR wt NSCLC cells. (A) mRNA expression levels of indicated genes were analyzed by quantitative PCR in ezrin-depleted
A549 cells. CT values were normalized to 18S rRNA, and fold differences were calculated using the comparative CT method. (B)
NSC305787 treatment did not decrease mRNA levels of nEGFR target genes in EGFR-null H520 cells, whereas AURKA and COX-2 levels
were decreased in wt EGFR H292 cells. (C) Ezrin and EGFR protein expression levels were determined by immunoblotting after
transfection of A549, H292, and H520 cells with siRNA oligos targeting ezrin. (D) Proliferation of A549, H292, and H520 cells after
transfection with siRNA oligos targeting ezrin was determined by MTT assay. Ezrin knockdown significantly decreased proliferation of wt
EGFR-expressing cells, A549 and H292, and did not affect EGFR-null cells, H520. (*P b .01, unpaired t test with Welch’s correction).
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anti-myc antibody revealed that wt (Supplementary Figure S6) and
phospho-mimicking ezrin Y146E mutant strongly interacts with
EGFR compared with phospho-null mutant Y146F (Figure 6C).
Ezrin Y353E and Y353F mutants did not interact with EGFR in
co-IP experiments (Supplementary Figure S2). We then compared
the IC50 values of erlotinib for mock-transfected, Ezrin
wt-, Y146E-,
and Y146F-expressing H2073 cells. Ezrinwt- and Y146E-expressing
cells showed resistance to erlotinib treatment unlike ezrin Y146F-
expressing cells (Figure 6D). Overexpression of ectopic ezrin Y146E
mutant in wt EGFR-expressing H2073 cells caused an increased
number of colonies in a soft agar colony formation assay (Figure 6E)
and cell proliferation (Figure 6F). EGFR-null H520 cells, on the
other hand, did not show any significant difference with any of the
ezrin expression constructs (Supplementary Figure S3).
Discussion
Promising characteristics of EGFR as a molecular target for cancer
therapy have inspired the development of targeted inhibitors against
EGFR and its signaling components. It has been reported that
combining distinct classes of EGFR inhibitors may not only
potentiate cellular toxicity but also assist to overcome inherent or
acquired resistance to a single class of EGFR inhibitors [34]. In the
current study, we showed for the first time that targeting ezrin
function with small molecule inhibitor might provide synergism in
combination with EGFR inhibition.
Ezrin is linked to different oncogenic phenotypes in different
tumor models [23]. Specifically, its role as a key regulator of
metastasis in osteosarcoma is well established [35]. Ezrin is involvedin a variety of cellular functions such as cell cytoskeleton organization,
cell motility, proliferation, cell signaling, and mRNA translation
[32,36,37]. But ezrin functioning on the plasma membrane may be
an independent process from its activities in the cytoplasm [29,38]. It
is likely that ezrin may regulate particular signaling pathways such as
Ras, Akt, and VEGFR in certain tumor types that may result in
diverse outcomes There are also accumulating data on the correlation
between ezrin expression and clinical outcomes in epithelial tumors;
however, the exact molecular mechanisms that result in these
oncologic phenotypes still remain unclear. In this study, we used two
wt EGFR-expressing NSCLC cell lines and showed that ezrin
interacts with EGFR and a small molecule inhibitor of ezrin,
NSC305787, inhibits this interaction. Downregulation of ezrin and
its pharmacological inhibition by NSC305787 caused a decreased
Y1068 and Y845 phosphorylation of EGFR and of common EGFR
downstream target proteins, ERK and STAT3, following EGF
treatment. Our findings support the growing list of unique ezrin
functions that contribute to oncogenesis.
Ezrin together with the homotypic fusion and protein sorting
complex regulates the maturation of early endosomes. Initiation of
the nuclear translocation of EGFR starts in early endosomes after
receptor internalization via its interaction with importin β1, and
depletion of ezrin causes a delay in EGFR trafficking in the
endosomes [31]. We observed decreased levels of nEGFR in
ezrin-knockdown NSCLC cells, although there were increases in
the total and cytoplasmic EGFR levels which might be a result of
positive feedback mechanisms or the act of Ezrin as a translation
regulator [32,36]. We also showed that expression of nEGFR target
genes AURKA, COX-2, and iNOS was significantly decreased in
Figure 5. Ezrin knockdown sensitizes NSCLC cells to erlotinib treatment. MTT test was used to evaluate the cell viability. (A) Nonlinear
curve fit and (B) IC50 values of control siRNA (siCTRL)– and siEZR-treated A549, H292, and H520 cells are given. Reduced ezrin expression
caused a decreased IC50 value for erlotinib in A549 and H292 cells compared with H520 cells. (C) Ezrin inhibitor NSC305787 shows
synergism with erlotinib in A549 cells. No synergy was observed in H520 cells treated with erlotinib-NSC305787 combination (D) and in
A549 cells treated with etoposide-NSC305787 combination (E).
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ezrin interaction with EGFR has functional significance. Experiments
with an EGFR-null cell line further validated that the observed
biological phenotypes in response to ezrin modulation were through
EGFR interaction.
The ezrin inhibitor NSC305787 has been shown to reduce
metastasis in experimental osteosarcoma model [35] and inhibit cell
survival in colorectal cancer cells [39]. Our data revealed that
NSC305787 diminished ezrin-EGFR interaction and caused de-
creased phosphorylation levels of downstream target genes ERK and
STAT3. NSC305787 also inhibited membranous localization of
ezrin and caused morphological changes in the cells.
Phosphorylation of ezrin is required both for conformational
activation and for signaling to downstream events [26]. C-terminal
threonine phosphorylation at T567 is the best known activating
phosphorylation site as a downstream target of Rho pathway [40].
Ezrin has been initially identified as a substrate for tyrosine
phosphorylation by EGFR [26,28], and recent studies have
demonstrated that growth factors EGF, PDGF, and HGF and Src
kinases are able to induce tyrosine phosphorylation of ezrin [41,42].
Phosphorylation of ezrin at Y353 is related to signal survival of PI3K/
Akt pathway [43] and has been shown to relate with late-stage and
poor differentiation in NSCLC [44]. Ezrin phosphorylation at Y146
is associated with adhesion-mediated signaling in A431 cells [42], but
the effect of this phosphorylation on EGFR interaction wasunknown. In this study, we showed that ezrin Y146E mutant more
strongly interacts with EGFR compared with phospho-null Y146F
mutant. Ectopic overexpression of ezrin Y146E mutant in wt
EGFR-expressing H2073 cells produced increased cell proliferation
and colony formation and caused erlotinib resistance.
Even though the discovery of the targeted receptor tyrosine kinase
inhibitors led to promising improvement in cancer treatment, they
failed to bring benefit as monotherapeutic drugs. This could be the
result of drug resistance or coactivation of other tyrosine kinase
receptors [45]. Particularly in NSCLC, different tyrosine kinase
receptors are active in cell lines and human tumor samples, and these
receptors mostly share common signaling pathways [46]. Therefore,
targeting intersecting pathways such as EGFR–c-MET or
EGFR-PDGFR pathways was beneficial in NSCLC and ovarian
cancer animal models [47–49]. Our findings were in support of this
hypothesis, as targeting ezrin function in NSCLC cells treated with
EGFR inhibitor shows synergism.
Overall, our findings show that ezrin regulates EGFR signaling and
trafficking to the nucleus; therefore, inhibiting ezrin function with
small molecule inhibitors may provide an effective combination with
EGFR inhibitors in EGFR-positive NSCLC. Further evaluation of
this synergism in in vivo models may accelerate clinical translation of
our findings for potential clinical applications.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.01.002.
Figure 6. Y146 phosphorylation of ezrin affects its interaction with EGFR. (A) The 100-ng/ml EGF treatment induces tyrosine
phosphorylation of ezrin on Y146 and Y353 residues in A549 cells. (B) Protein expression levels of myc-tagged Ezrinwt, Y146E, and Y146F
were determined by immunoblotting following transfection of H2073 cells with corresponding expression constructs. (C) Ezrin-EGFR
interaction in H2073 cells transfected with cDNAs coding for ezrin Y146E and Y146F mutants was determined by immunoprecipitation
using anti-myc antibody followed by Western blotting. (D) Ectopic expression of ezrinwt and ezrin Y146E mutant sensitizes cells to
erlotinib in H2073 cells. IC50 values are given in the table, and cell viability curves are shown in the graph. (E) The number of colonies in
H2073 cells transfected with cDNAs coding for ezrin Y145E and Y145Fmutants was determined by soft agar colony formation assay (*P b
.01, unpaired t test with Welch’s correction). (F) Ectopic overexpression of ezrinwt and ezrin Y146E mutant caused an increased
proliferation of H2073 cells compared with ezrin Y146F mutant.
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